Celldex Therapeutics, Inc. (CLDX)
| Market Cap | 2.52B +91.4% |
| Revenue (ttm) | 865,000 -88.6% |
| Net Income | -283.65M |
| EPS | -4.27 |
| Shares Out | 78.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,007,153 |
| Open | 31.29 |
| Previous Close | 31.27 |
| Day's Range | 31.05 - 32.21 |
| 52-Week Range | 19.52 - 35.79 |
| Beta | 0.93 |
| Analysts | Strong Buy |
| Price Target | 57.53 (+79.11%) |
| Earnings Date | May 7, 2026 |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias,... [Read more]
Financial Performance
In 2025, Celldex Therapeutics's revenue was $1.55 million, a decrease of -77.99% compared to the previous year's $7.02 million. Losses were -$258.76 million, 63.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price target is $57.53, which is an increase of 79.11% from the latest price.
News
Celldex presents long-term results from Phase 2 study of barzolvolimab
Celldex (CLDX) announced the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology, EAACI,…
Celldex presents first-in-human results for CDX-622
Celldex (CLDX) presented positive results from the Phase 1 healthy participant study of CDX-622 at the European Academy of Allergy and Clinical Immunology, EAACI, Annual Meeting in Istanbul, Turkiye. ...
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the Euro...
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets...
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) a...
Celldex price target raised to $45 from $38 at UBS
UBS raised the firm’s price target on Celldex (CLDX) to $45 from $38 and keeps a Buy rating on the shares. Barzolvolimab’s CSU Phase 3 set-up is favorable for potential…
Celldex Therapeutics Slides: Corporate presentation
Celldex Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Celldex price target raised to $54 from $38 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on Celldex (CLDX) to $54 from $38 and keeps an Overweight rating on the shares. The firm is getting more…
Celldex price target raised to $38 from $34 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Celldex (CLDX) to $38 from $34 and keeps a Neutral rating on the shares.
Celldex price target raised to $48 from $45 at Barclays
Barclays raised the firm’s price target on Celldex (CLDX) to $48 from $45 and keeps an Overweight rating on the shares.
Celldex sees funds sufficient to fund current planned operations through 2028
Celldex (CLDX) believes that the cash, cash equivalents and marketable securities at March 31, along with the approximately $323.9M in net proceeds from its April underwritten public offering, are suf...
Celldex Reports First Quarter Financial Results and Provides Corporate Update
HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.
Celldex Therapeutics Earnings release: Q1 2026
Celldex Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Celldex Therapeutics Quarterly report: Q1 2026
Celldex Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Celldex Therapeutics Proxy statement: Proxy filing
Celldex Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)
Celldex stock was on the move Monday alongside an upgrade and increased price target from a top Wall Street analyst.
Celldex upgraded to Overweight from Underweight at Barclays
Barclays upgraded Celldex (CLDX) to Overweight from Underweight with a price target of $45, up from $24. The firm has conviction in a successful Phase 3 readout in chronic spontaneous…
Celldex Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Barzolvolimab demonstrates rapid, durable, and high complete response rates in urticaria, with phase III data expected in Q4. Positioned for both first- and second-line advanced therapy markets, the company is well-funded and advancing a promising pipeline, including CDX-622.
Celldex to Present at Upcoming Investor Conference
HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Vi...
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public off...
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 sh...
Celldex announces common stock offering, no amount given
Celldex (CLDX) Therapeutics announced that it has commenced an underwritten public offering for the sale of shares of its common stock. Celldex currently intends to use the net proceeds of…
Celldex Announces Proposed Public Offering of Common Stock
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the s...
Celldex data shows improvements across six DLQI Domains in barzolvolimab trials
Celldex (CLDX) presented additional data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria and cold urticaria and symptomatic dermographism demonstrating pro...
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life - - Data further d emonstrates first-in-class and best-in-disease barzolvolimab profile -